With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences, Inc. GILD announced that the investigational single-tablet regimen of bictegravir and lenacapavir for the ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Knowable Magazine reports on breakthroughs in HIV treatment; engineered antibodies show promise for long-term control, ...

A natural vitamin A transporter, RBP4, can awaken latent HIV through NF-κB signalling, offering a new angle for cure strategies. Human immunodeficiency virus (HIV) is a virus that attacks key immune ...

Since the human immunodeficiency virus (HIV) was identified in 1983, roughly 91.4 million people around the world have contracted the virus and an additional 44.1 million have died from related causes ...

Two studies suggest that T cells with stem-cell-like properties could work with antibody therapies to control HIV after a person stops taking antiviral pills.

According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million ...

Today, we confront emerging threats from a range of respiratory viruses, insect-transmitted viruses, and viruses we have not ...

HIV treatment has significantly evolved over the past 30 years, transforming HIV from a fatal disease to a manageable chronic condition. Despite advances, challenges remain in treatment access, stigma ...

A federally funded clinical trial suggests knowing HIV viral load (number of HIV particles in the body) doesn’t improve the ...